| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Respiratory Oncology Unit, Dept of Pulmonology and 2 PET-Centre, Dept of Nuclear Medicine, University Hospital Gasthuisberg, Catholic University Leuven, Belgium
CORRESPONDENCE: J.F. Vansteenkiste, Respiratory Oncology Unit, Dept of Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium. Fax: 3216346803
Keywords: decision trees, emission computed tomography, 18F-fluoro-2-deoxy-d-glucose, lung neoplasms, non-small cell lung carcinoma, predictive value of tests
Received: October 12, 2000
Accepted January 10, 2001
This data was presented in part in the review-of-the-decade lecture at the 2000 Florence meeting of the European Respiratory Society
Abstract
In the past 5 yrs, positron emission tomography (PET) with 18F-fluoro-2-deoxy-d-glucose (FDG) has become an important imaging modality in lung cancer patients. At this time, the indication of FDG-PET as a complimentary tool to computed tomography in the diagnosis and staging of non-small cell lung cancer has gradually gained more widespread acceptance and also reimbursement in many European countries.
This review focuses on the data of FDG-PET in the diagnosis of lung nodules and masses, and in locoregional and extrathoracic staging of non-small cell lung cancer. Emphasis is put on the potential clinical implementation of the currently available FDG-PET data. The use of FDG-PET in these indications now needs further validation in large-scale multicentre randomized studies, focusing mainly on treatment outcome parameters, survival and cost-efficacy.
Interesting findings with 18F-fluoro-2-deoxy-d-glucose-positron emission tomography have also been reported for the evaluation of response to radio- or chemotherapy, in radiotherapy planning, recurrence detection and assessment of prognosis. Finally, a whole new field of application of positron emission tomography in molecular biology, using new radiopharmaceuticals, is under extensive investigation.
This article has been cited by other articles:
|
|
 |
|
  G. Veronesi, M. Bellomi, U. Veronesi, G. Paganelli, P. Maisonneuve, P. Scanagatta, F. Leo, G. Pelosi, L. Travaini, C. Rampinelli, et al. Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening Ann. Thorac. Surg., September 1, 2007; 84(3): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fischer, J Mortensen, S. Langer, A Loft, A. Berthelsen, B. Petersen, G Daugaard, U Lassen, and H. Hansen A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis Ann. Onc., February 1, 2007; 18(2): 338 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Daniels, V. J. Lowe, M.-C. Aubry, M. S. Allen, and J. R. Jett The Utility of Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Carcinoid Tumors Presenting as Pulmonary Nodules Chest, January 1, 2007; 131(1): 255 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Plat, P. Pierard, A. Haller, J. Hutsebaut, J. Faber, M. Dusart, P. Eisendrath, J-P. Sculier, and V. Ninane Endobronchial ultrasound and positron emission tomography positive mediastinal lymph nodes Eur. Respir. J., February 1, 2006; 27(2): 276 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer Oncologist, November 1, 2004; 9(6): 633 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.F. Vansteenkiste Imaging in lung cancer: positron emission tomography scan Eur. Respir. J., February 1, 2002; 19(35_suppl): 49S - 60s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.L. Muller Advances in imaging Eur. Respir. J., November 1, 2001; 18(5): 867 - 871. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
